Clinical trial

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

NCT04032080

Study summary

ClinicalTrials.gov

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

COMBINATION_PRODUCT · Unmapped registry intervention Drug 1: LY3023414; Drug 2: Prexasertib Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-09-05

PhasePHASE2

Conditions

Triple Negative Breast Cancerunresolved

Interventions

Drug 1: LY3023414; Drug 2: PrexasertibCOMBINATION_PRODUCT

Sponsors & collaborators

Baylor Research Institutelead sponsor

Eli Lilly and Companycollaborator

Mapped research locations

DallasTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04032080 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.